<p>MannKind Corporation（納斯達克代碼：MNKD - 免費報告）- HC Wainwright 的股票分析師在 9 月 2 日（星期二）向客户和投資者發佈的研究報告中提高了對 MannKind 2028 財年每股收益的預期。HC Wainwright 的分析師 B. Folkes 現在預計這家生物製藥公司將在該年度發佈每股收益 0.38 美元，高於之前預測的 0.37 美元。HC Wainwright 對該股票給予 “買入” 評級，目標價為 11.00 美元。市場普遍預計 MannKind 當前全年的每股收益為 0.10 美元。HC Wainwright 還對 MannKind 2029 財年的每股收益預期為 0.65 美元。</p>
<p>其他一些股票分析師最近也發佈了關於 MNKD 的報告。富國銀行將 MannKind 的目標價從 9.00 美元上調至 10.00 美元，並在週三的報告中給予該股票 “超配” 評級。加拿大皇家銀行在 8 月 26 日（星期二）的報告中將 MannKind 的目標價從 7.00 美元上調至 8.00 美元，並給予該公司 “跑贏大盤” 評級。最後，華爾街 Zen 在 8 月 2 日（星期六）的報告中將 MannKind 的評級從 “買入” 下調至 “持有”。兩位研究分析師對該股票給予 “強烈買入” 評級，五位分析師給予該公司股票 “買入” 評級。根據 MarketBeat 的數據，該公司目前的平均評級為 “買入”，平均目標價為 10.00 美元。</p>
<p><strong>查看我們最新的 MNKD 股票報告</strong></p>
<h2>MannKind 股價下跌 4.0%</h2>
<p>MNKD 的股票在週四以 5.51 美元開盤。MannKind 的 1 年最低價為 3.38 美元，1 年最高價為 7.63 美元。該股票的市值為 16.9 億美元，市盈率為 50.10，貝塔值為 1.02。該股票的 50 日移動平均價格為 3.93 美元，200 日移動平均價格為 4.44 美元。</p>
<p>MannKind（納斯達克代碼：MNKD - 獲取免費報告）最近在 8 月 6 日（星期三）發佈了其財報。這家生物製藥公司報告本季度每股收益為 0.05 美元，超出分析師一致預期的 0.04 美元，超出幅度為 0.01 美元。MannKind 的股本回報率為-32.60%，淨利潤率為 10.87%。該公司本季度的收入為 7653 萬美元，而分析師預期為 7782 萬美元。去年同期，該公司每股收益為 0.05 美元。與去年同期相比，該公司的收入增長了 5.7%。</p>
<h2>MannKind 的內部買賣</h2>
<p>在其他消息中，董事 Steven B. Binder 在 7 月 16 日（星期三）出售了 75367 股 MannKind 股票。該股票以平均價格 3.94 美元出售，總交易額為 296,945.98 美元。交易後，該董事在公司持有 830,508 股，價值 3,272,201.52 美元。此次交易使其持股減少了 8.32%。該交易已在向 SEC 提交的文件中披露，文件可在此鏈接查看。公司內部人士持有 3.00% 的股票。</p>
<h2>機構投資者對 MannKind 的看法</h2>
<p>一些對沖基金和其他機構投資者最近也買賣了 MNKD 的股票。Dimensional Fund Advisors LP 在第四季度將其在 MannKind 的持倉增加了 40.7%。Dimensional Fund Advisors LP 現在持有 2958219 股該生物製藥公司的股票，價值 19022000 美元，此前在上個季度又購買了 855261 股。滙豐控股在第四季度將其在 MannKind 的持倉增加了 49.7%。滙豐控股現在持有 31327 股該生物製藥公司的股票，價值 203000 美元，此前在上個季度又購買了 10407 股。Price T Rowe Associates Inc. MD 在第四季度將其在 MannKind 的持倉增加了 12.0%。Price T Rowe Associates Inc. MD 現在持有 175009 股該生物製藥公司的股票，價值 1126000 美元，此前在上個季度又購買了 18806 股。北方信託公司在第四季度將其在 MannKind 的持倉增加了 8.1%。北方信託公司現在持有 2777784 股該生物製藥公司的股票，價值 17861000 美元，此前在上個季度又購買了 207792 股。最後，Ameriprise Financial Inc.在第四季度將其在 MannKind 的持倉增加了 145.4%。Ameriprise Financial Inc.現在持有 43685 股該生物製藥公司的股票，價值 281000 美元，此前在上個季度又購買了 25880 股。機構投資者和對沖基金持有該公司 49.55% 的股票。</p>
<h2>MannKind 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>MannKind Corporation 是一家生物製藥公司，專注於在美國開發和商業化用於內分泌和孤兒肺病的吸入治療產品。它提供 Afrezza，一種用於改善糖尿病成人血糖控制的吸入胰島素，以及 V-Go 可穿戴胰島素輸送設備，提供成人的持續皮下胰島素輸注。</p>
<h2>閲讀更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過 MannKind</li>
<li>CD 計算器：定期存款計算器</li>
<li>ETF 的回報：3 個可能持續超越的名字</li>
<li>投資於高市盈率成長股</li>
<li>開學購物達到 400 億美元：3 只值得關注的零售股票</li>
<li>10 月值得考慮購買的 3 只股票</li>
<li>字母表股票在躲避嚴厲的反壟斷措施後大幅上漲</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TU5LRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TU5LRA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 MannKind 嗎？</h2>
<p>在你考慮 MannKind 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 MannKind 並不在名單上。</p>
<p>雖然 MannKind 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

曼恩凱德生物醫療

<p>HC Wainwright 將 MannKind Corporation (NASDAQ:MNKD) 的 2028 財年每股收益預期從 0.37 美元上調至 0.38 美元，維持 “買入” 評級，目標價為 11.00 美元。其他分析師也提高了他們的目標價，富國銀行將其上調至 10.00 美元，加拿大皇家銀行則上調至 8.00 美元。MannKind 當前的收益共識為每股 0.10 美元。該股票開盤價為 5.51 美元，市值為 16.9 億美元，市盈率為 50.10。還注意到內部交易活動和機構投資</p>

<p>MannKind Corporation (NASDAQ:MNKD - Free Report) - Stock analysts at HC Wainwright increased their FY2028 earnings per share estimates for MannKind in a research report issued to clients and investors on Tuesday, September 2nd. HC Wainwright analyst B. Folkes now expects that the biopharmaceutical company will post earnings per share of $0.38 for the year, up from their prior forecast of $0.37. HC Wainwright has a &#34;Buy&#34; rating and a $11.00 price target on the stock. The consensus estimate for MannKind's current full-year earnings is $0.10 per share. HC Wainwright also issued estimates for MannKind's FY2029 earnings at $0.65 EPS.</p>
<div class="lb-trans"><p>MannKind Corporation（納斯達克代碼：MNKD - 免費報告）- HC Wainwright 的股票分析師在 9 月 2 日（星期二）向客户和投資者發佈的研究報告中提高了對 MannKind 2028 財年每股收益的預期。HC Wainwright 的分析師 B. Folkes 現在預計這家生物製藥公司將在該年度發佈每股收益 0.38 美元，高於之前預測的 0.37 美元。HC Wainwright 對該股票給予 “買入” 評級，目標價為 11.00 美元。市場普遍預計 MannKind 當前全年的每股收益為 0.10 美元。HC Wainwright 還對 MannKind 2029 財年的每股收益預期為 0.65 美元。</p>
</div><p>A number of other equities analysts have also recently issued reports on MNKD. Wells Fargo &amp; Company raised their target price on MannKind from $9.00 to $10.00 and gave the stock an &#34;overweight&#34; rating in a report on Wednesday. Royal Bank Of Canada lifted their price objective on MannKind from $7.00 to $8.00 and gave the company an &#34;outperform&#34; rating in a report on Tuesday, August 26th. Finally, Wall Street Zen cut MannKind from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, August 2nd. Two research analysts have rated the stock with a Strong Buy rating and five have given a Buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of &#34;Buy&#34; and an average target price of $10.00.</p>
<div class="lb-trans"><p>其他一些股票分析師最近也發佈了關於 MNKD 的報告。富國銀行將 MannKind 的目標價從 9.00 美元上調至 10.00 美元，並在週三的報告中給予該股票 “超配” 評級。加拿大皇家銀行在 8 月 26 日（星期二）的報告中將 MannKind 的目標價從 7.00 美元上調至 8.00 美元，並給予該公司 “跑贏大盤” 評級。最後，華爾街 Zen 在 8 月 2 日（星期六）的報告中將 MannKind 的評級從 “買入” 下調至 “持有”。兩位研究分析師對該股票給予 “強烈買入” 評級，五位分析師給予該公司股票 “買入” 評級。根據 MarketBeat 的數據，該公司目前的平均評級為 “買入”，平均目標價為 10.00 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on MNKD</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 MNKD 股票報告</strong></p>
</div><h2>MannKind Trading Down 4.0%</h2>
<div class="lb-trans"><h2>MannKind 股價下跌 4.0%</h2>
</div><p>Shares of MNKD opened at $5.51 on Thursday. MannKind has a 1 year low of $3.38 and a 1 year high of $7.63. The stock has a market cap of $1.69 billion, a P/E ratio of 50.10 and a beta of 1.02. The stock's 50-day moving average price is $3.93 and its two-hundred day moving average price is $4.44.</p>
<div class="lb-trans"><p>MNKD 的股票在週四以 5.51 美元開盤。MannKind 的 1 年最低價為 3.38 美元，1 年最高價為 7.63 美元。該股票的市值為 16.9 億美元，市盈率為 50.10，貝塔值為 1.02。該股票的 50 日移動平均價格為 3.93 美元，200 日移動平均價格為 4.44 美元。</p>
</div><p>MannKind (NASDAQ:MNKD - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.04 by $0.01. MannKind had a negative return on equity of 32.60% and a net margin of 10.87%.The firm had revenue of $76.53 million for the quarter, compared to analysts' expectations of $77.82 million. During the same quarter last year, the business earned $0.05 earnings per share. The company's revenue was up 5.7% compared to the same quarter last year.</p>
<div class="lb-trans"><p>MannKind（納斯達克代碼：MNKD - 獲取免費報告）最近在 8 月 6 日（星期三）發佈了其財報。這家生物製藥公司報告本季度每股收益為 0.05 美元，超出分析師一致預期的 0.04 美元，超出幅度為 0.01 美元。MannKind 的股本回報率為-32.60%，淨利潤率為 10.87%。該公司本季度的收入為 7653 萬美元，而分析師預期為 7782 萬美元。去年同期，該公司每股收益為 0.05 美元。與去年同期相比，該公司的收入增長了 5.7%。</p>
</div><h2>Insider Buying and Selling at MannKind</h2>
<div class="lb-trans"><h2>MannKind 的內部買賣</h2>
</div><p>In other news, Director Steven B. Binder sold 75,367 shares of MannKind stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $3.94, for a total transaction of $296,945.98. Following the transaction, the director owned 830,508 shares in the company, valued at $3,272,201.52. The trade was a 8.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.00% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他消息中，董事 Steven B. Binder 在 7 月 16 日（星期三）出售了 75367 股 MannKind 股票。該股票以平均價格 3.94 美元出售，總交易額為 296,945.98 美元。交易後，該董事在公司持有 830,508 股，價值 3,272,201.52 美元。此次交易使其持股減少了 8.32%。該交易已在向 SEC 提交的文件中披露，文件可在此鏈接查看。公司內部人士持有 3.00% 的股票。</p>
</div><h2>Institutional Investors Weigh In On MannKind</h2>
<div class="lb-trans"><h2>機構投資者對 MannKind 的看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently bought and sold shares of MNKD. Dimensional Fund Advisors LP raised its position in MannKind by 40.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,958,219 shares of the biopharmaceutical company's stock valued at $19,022,000 after buying an additional 855,261 shares during the last quarter. Hsbc Holdings PLC raised its position in MannKind by 49.7% in the 4th quarter. Hsbc Holdings PLC now owns 31,327 shares of the biopharmaceutical company's stock valued at $203,000 after buying an additional 10,407 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in MannKind by 12.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 175,009 shares of the biopharmaceutical company's stock valued at $1,126,000 after buying an additional 18,806 shares during the last quarter. Northern Trust Corp raised its position in MannKind by 8.1% in the 4th quarter. Northern Trust Corp now owns 2,777,784 shares of the biopharmaceutical company's stock valued at $17,861,000 after buying an additional 207,792 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its position in MannKind by 145.4% in the 4th quarter. Ameriprise Financial Inc. now owns 43,685 shares of the biopharmaceutical company's stock valued at $281,000 after buying an additional 25,880 shares during the last quarter. Institutional investors and hedge funds own 49.55% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近也買賣了 MNKD 的股票。Dimensional Fund Advisors LP 在第四季度將其在 MannKind 的持倉增加了 40.7%。Dimensional Fund Advisors LP 現在持有 2958219 股該生物製藥公司的股票，價值 19022000 美元，此前在上個季度又購買了 855261 股。滙豐控股在第四季度將其在 MannKind 的持倉增加了 49.7%。滙豐控股現在持有 31327 股該生物製藥公司的股票，價值 203000 美元，此前在上個季度又購買了 10407 股。Price T Rowe Associates Inc. MD 在第四季度將其在 MannKind 的持倉增加了 12.0%。Price T Rowe Associates Inc. MD 現在持有 175009 股該生物製藥公司的股票，價值 1126000 美元，此前在上個季度又購買了 18806 股。北方信託公司在第四季度將其在 MannKind 的持倉增加了 8.1%。北方信託公司現在持有 2777784 股該生物製藥公司的股票，價值 17861000 美元，此前在上個季度又購買了 207792 股。最後，Ameriprise Financial Inc.在第四季度將其在 MannKind 的持倉增加了 145.4%。Ameriprise Financial Inc.現在持有 43685 股該生物製藥公司的股票，價值 281000 美元，此前在上個季度又購買了 25880 股。機構投資者和對沖基金持有該公司 49.55% 的股票。</p>
</div><h2>MannKind Company Profile</h2>
<div class="lb-trans"><h2>MannKind 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.</p>
<div class="lb-trans"><p>MannKind Corporation 是一家生物製藥公司，專注於在美國開發和商業化用於內分泌和孤兒肺病的吸入治療產品。它提供 Afrezza，一種用於改善糖尿病成人血糖控制的吸入胰島素，以及 V-Go 可穿戴胰島素輸送設備，提供成人的持續皮下胰島素輸注。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>閲讀更多</h2>
</div><ul>
<li>Five stocks we like better than MannKind</li>
<li>CD Calculator: Certificate of Deposit Calculator</li>
<li>Return of the ETFs: 3 Names That Could Keep Outperforming</li>
<li>Investing in the High PE Growth Stocks</li>
<li>Back-to-School Shopping Hits $40B: 3 Retail Stocks to Watch Now</li>
<li>3 Stocks to Consider Buying in October</li>
<li>Alphabet Stock Surges After Dodging Harsh Antitrust Remedies</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 MannKind</li>
<li>CD 計算器：定期存款計算器</li>
<li>ETF 的回報：3 個可能持續超越的名字</li>
<li>投資於高市盈率成長股</li>
<li>開學購物達到 400 億美元：3 只值得關注的零售股票</li>
<li>10 月值得考慮購買的 3 只股票</li>
<li>字母表股票在躲避嚴厲的反壟斷措施後大幅上漲</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TU5LRA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=MNKD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MannKind Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 MannKind 嗎？</h2>
</div><p>Before you consider MannKind, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 MannKind 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MannKind wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 MannKind 並不在名單上。</p>
</div><p>While MannKind currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 MannKind 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

HC Wainwright 上調了曼恩凱德生物醫療 2028 財年的每股收益預期